2019 Fall Conference | N2 - Neuroscience in the Clinic: Headache

Date Saturday 10/19/19

Time 10:00 AM - 11:30 AM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Neuroscience in the Clinic Session

Director(s) Dawn C. Buse, PhD

Topic(s) Headache

Learning Objectives Upon completion, participants should display knowledge of the prevalence of depression and anxiety among people with migraine as well as the associated effects on outcomes, disability, quality of life, additional comorbidities, adherence and motivation; display knowledge and understanding of the validated tools to assess for these comorbidities and how to track changes in status as part of clinical care; and display knowledge of how to treat migraine with psychopharmacologic and non-pharmacologic treatment options among patients with psychiatric comorbidities as well as knowledge on how to treat or refer for treatment for the psychiatric comorbidities themselves.

CME Available 1.50 CME credits

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Case-based, Didactic

Program Materials Program Evaluations

Event Timeline
10:00 AM - 10:05 AM	Introduction	Introduction and Objectives Dawn C. Buse, PhD
10:05 AM - 10:25 AM	Speaker	Overview of Migraine and Psychiatric Co-morbidity Epidemiology and Their Shared Pathophysiology; Overview of Migraine Criteria, Depression Criteria, and Anxiety Criteria Mia T. Minen, MD, FAAN
10:25 AM - 10:35 AM	Speaker	Overview of Assessment of Psychiatric Co-morbidity and Migraine-related Disability Dawn C. Buse, PhD
10:35 AM - 11:05 AM	Speaker	Clinical Management of Migraine and Psychiatric Co-morbidities Noah Rosen, MD, FAAN
11:05 AM - 11:20 AM	Speaker	Behavioral Management of Migraine and Psychiatric Co-morbidities, Review of Empirically Supported Treatments, How to Make Successful Referrals, and How and Where to Find Providers Dawn C. Buse, PhD
11:20 AM - 11:30 AM	Q&A	Questions and Answers/Panel Discussion

Faculty Disclosures
Dawn C. Buse, PhD	Dr. Buse has received personal compensation for serving as an employee of Vector Psychometric Group. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranicsa. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Buse has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. The institution of Dr. Buse has received research support from Amgen. The institution of Dr. Buse has received research support from FDA. The institution of Dr. Buse has received research support from National Headache Foundation.
Noah Rosen, MD, FAAN	Dr. Rosen has received personal compensation for serving as an employee of Northwell Health. An immediate family member of Dr. Rosen has received personal compensation for serving as an employee of New York University. Dr. Rosen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/ Abbvie. Dr. Rosen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Rosen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer . Dr. Rosen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan/ Abbvie. Dr. Rosen has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Speaker with American Headache Society.
Mia T. Minen, MD, FAAN	The institution of Dr. Minen has received research support from NIH. Dr. Minen has received intellectual property interests from a discovery or technology relating to health care. Dr. Minen has received personal compensation in the range of $500-$4,999 for serving as a First Contact-Primary Care Advisory Board Member with American Headache Society . Dr. Minen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PCORI grant on migraine evidence based map for stakeholders with ECRI .

��ɫ��

��ɫ��